Translate
Traws Pharma, Inc.
About
1.53USD-0.05 -3.16%
Closed • Updated at 08:05 GMT+00:00Market Cap$23.18M
Volume1.31M
Beta-0.70
RSI47.35
Gross Margin96.19%
Traws Pharma, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 15 2026
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
May 8 2026
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Apr 15 2026
Traws Pharma Announces Up to $60 Million Private Placement Financing
Feb 19 2026
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Jan 26 2026
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Recent Videos
Traws Pharma Q4 2025: $60M Financing & Flu Antiviral Breakthrough
May 23, 2026
$TRAW Traws Pharma Q4 2025 Earnings Conference Call
May 20, 2026
TRAW Stock TOMORROW UPDATE! (The Exact Answer!) Traws Pharma stock analysis today
May 10, 2026
¡BOMBAZO CIENTÍFICO ARTIVA! 🧬.TRAWS entra en HANTAVIRUS ¿Humo o Realidad?. Noticias Biotech Hoy
May 08, 2026
Community Chat
Ask AI
Try asking